NY-ESO-1 and survivin were tested to drive cellular proliferation and IFN-γ production in blood from patients with GBM, as well as to control antigens, including frequently recognized Flu targets (H1N1, H1N5), as well as to negative controls, e.g., Mycobacterium tuberculosis targets (Supplementary Figs. 2a, b and 3). The gene discussed is BIRC5; the disease is glioblastoma.